Josep Muncunill1,2, Maria-Joao Baptista1,2, Águeda Hernandez-Rodríguez3, Judith Dalmau4, Olga Garcia1,2, Gustavo Tapia5, Miriam Moreno1,2, Juan-Manuel Sancho1,2, Javier Martínez-Picado4,6,7, Evarist Feliu1,2, José-Luis Mate5, Josep-Maria Ribera1,2, José-Tomás Navarro1,2. 1. Department of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona. 2. Josep Carreras Leukaemia Research Institute, IJC Can Ruti Campus. 3. Department of Microbiology, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona. 4. IrsiCaixa AIDS Research Institute, Universitat Autònoma de Barcelona, Badalona. 5. Department of Pathology, Germans Trias i Pujol Hospital, Universitat Autònoma de Barcelona, Badalona. 6. University of Vic-Central University of Catalonia, Vic. 7. Catalan Institution for Research and Advanced Studies, Barcelona, Spain.
Abstract
BACKGROUND: Epstein-Barr virus (EBV) has been implicated in lymphomagenesis and can be found infecting tumor cells and in plasma at lymphoma diagnosis, especially in human immunodeficiency virus (HIV)-infected patients. Our aim was to evaluate the usefulness of plasma EBV load as biomarker and prognostic factor in HIV-positive patients with lymphomas. METHODS: EBV loads were measured by polymerase chain reaction in plasma samples of 81 HIV-positive patients' lymphomas at different moments: within 1 year before lymphoma diagnosis, at diagnosis, and at complete response (CR). Control samples included HIV-negative patients with lymphomas and HIV-positive patients without neoplasia or opportunistic infections. RESULTS: HIV-positive patients with lymphomas had more frequently-detectable EBV load at lymphoma diagnosis (53%) than either HIV-negative patients with the same lymphoma type (16%; P < .001) or HIV-positive individuals without neoplasia or opportunistic infection (1.2%; P < .001). HIV-positive lymphoma patients with detectable EBV load in plasma at lymphoma diagnosis had statistically significant decrease of EBV load at CR. High EBV load (>5000 copies/mL) at lymphoma diagnosis was an independent negative prognostic factor for overall survival and progression-free survival in HIV-positive patients with lymphomas. Detectable plasma EBV loads identified HIV-positive subjects that would eventually develop lymphoma (area under the curve, 82%; 95% CI: 0.67-0.96). CONCLUSIONS: Plasma EBV load can be used as a biomarker and as a prognostic factor in HIV-positive patients with lymphomas. The presence of the EBV load in the plasma of an HIV-positive patient can be an early predictor of lymphoma development.
BACKGROUND: Epstein-Barr virus (EBV) has been implicated in lymphomagenesis and can be found infecting tumor cells and in plasma at lymphoma diagnosis, especially in human immunodeficiency virus (HIV)-infectedpatients. Our aim was to evaluate the usefulness of plasma EBV load as biomarker and prognostic factor in HIV-positivepatients with lymphomas. METHODS:EBV loads were measured by polymerase chain reaction in plasma samples of 81 HIV-positivepatients' lymphomas at different moments: within 1 year before lymphoma diagnosis, at diagnosis, and at complete response (CR). Control samples included HIV-negative patients with lymphomas and HIV-positivepatients without neoplasia or opportunistic infections. RESULTS:HIV-positivepatients with lymphomas had more frequently-detectable EBV load at lymphoma diagnosis (53%) than either HIV-negative patients with the same lymphoma type (16%; P < .001) or HIV-positive individuals without neoplasia or opportunistic infection (1.2%; P < .001). HIV-positive lymphomapatients with detectable EBV load in plasma at lymphoma diagnosis had statistically significant decrease of EBV load at CR. High EBV load (>5000 copies/mL) at lymphoma diagnosis was an independent negative prognostic factor for overall survival and progression-free survival in HIV-positivepatients with lymphomas. Detectable plasma EBV loads identified HIV-positive subjects that would eventually develop lymphoma (area under the curve, 82%; 95% CI: 0.67-0.96). CONCLUSIONS: Plasma EBV load can be used as a biomarker and as a prognostic factor in HIV-positivepatients with lymphomas. The presence of the EBV load in the plasma of an HIV-positivepatient can be an early predictor of lymphoma development.
Authors: Jeffrey A Bailey; Ann M Moormann; Yasin Kaymaz; Cliff I Oduor; Ozkan Aydemir; Micah A Luftig; Juliana A Otieno; John Michael Ong'echa Journal: J Virol Date: 2020-08-17 Impact factor: 5.103
Authors: Nathan D Montgomery; Cara Randall; Matthew Painschab; Ryan Seguin; Bongani Kaimila; Edwards Kasonkanji; Takondwa Zuze; Robert Krysiak; Marcia K Sanders; Avian Elliott; Melissa B Miller; Coxcilly Kampani; Fred Chimzimu; Maurice Mulenga; Blossom Damania; Tamiwe Tomoka; Yuri Fedoriw; Dirk P Dittmer; Satish Gopal Journal: Cancer Med Date: 2019-11-29 Impact factor: 4.452